Mesh Bio is a pioneering brand in the field of healthcare, offering clinically actionable solutions in clinical decision support and patient management. Their mission is to provide healthcare providers and ecosystem stakeholders with the tools they need to change patient trajectories and improve outcomes. Mesh Bio focuses on transforming chronic disease management through the power of predictive analytics.

By utilizing multidimensional patient data, they enable personalized precision medicine in the management of cardiometabolic diseases, ultimately aiming to prevent catastrophic patient outcomes. The brand is led by a team of accomplished leaders, including co-founders Andrew Wu, who brings his expertise in cancer diagnostics technology, and Arsen Batagov, a bioinformatics and systems biology specialist. Dr.

Melvin Heng, co-founder and medical advisor, is dedicated to utilizing digital technologies for healthcare delivery. Mesh Bio also boasts a talented executive team and a distinguished board of directors and advisors. With their innovative solutions and commitment to improving patient care, Mesh Bio is at the forefront of revolutionizing healthcare management